At Asphalion, we are strongly committed to driving digitalization and integrating innovative tools to enhance our work. We believe that the thoughtful and responsible use of digital solutions, such as Artificial Intelligence, can significantly help improve project outcomes. That’s why we continuously explore new automation strategies to optimize our processes.
Continuing our revision of the different key authorities shaping the future of AI in healthcare, we find the Uppsala Reports, the news site of Uppsala Monitoring Centre. Recently, they published a report on “Artificial intelligence in pharmacovigilance: Harnessing potential, navigating risks”.
This report underscores AI’s transformative potential for pharmacovigilance while emphasizing the importance of navigating its risks through critical assessment and collaboration. Here the highlights of said document:
- Growing Interest in AI: There is a rapidly growing interest in the potential benefits AI solutions can bring to pharmacovigilance and wider society. Contributions in this issue from experts like Michael Glaser highlight the need to build trust in AI without always revealing or understanding its underlying parameters or data.
- AI Applications in Pharmacovigilance: AI applications include disproportionality analysis, syndrome detection, predictive models for signal detection, and processing regulatory and scientific texts. AI aims to boost efficiency, quality, and capability, often through collaboration with human intelligence for intelligence augmentation.
- Critical Assessment of AI: It’s crucial for pharmacovigilance professionals and decision-makers to assess AI solutions critically.
- Generative AI: Generative AI introduces new performance levels using large neural networks and zero-shot learning, offering potential improvements in some tasks. However, for tasks like large-scale duplicate detection or sensitive case triaging, traditional machine learning may be more suitable due to speed and reproducibility concerns.
Read the whole document here: https://bit.ly/3IUyAL3
Need help in your regulatory endeavours? Contact us at: [email protected]
